Company Overview of Octapharma AG
Octapharma AG, a plasma fractionation company, develops, produces, and sells human proteins that are derived from human plasma and human cell-lines in Europe and internationally. It offers haematology products, such as Nuwiq, a human coagulation factor VIII recombinant DNA for the treatment and prophylaxis of bleeding in all age groups with haemophilia A; octanate, a human factor VIII/von Willebrand factor (VWF) concentrate, which is used for the prophylaxis and treatment of bleeding in haemophilia A patients; wilate, a human VWF concentrate to treat von Willebrand disease and haemophilia A patients; and octanine F, a human factor IX concentrate for the prophylaxis and treatment of bleeding ...
Founded in 1983
Key Executives for Octapharma AG
Chairman of Management Board and Chief Executive Officer
Chief Financial Officer and Member of Management Board
Member of Management Board and President of Octapharma Plasma Inc USA
Member of Management Board and President of Octapharma USA INC
Senior Vice President of R&D Plasma - Vienna
Compensation as of Fiscal Year 2016.
Octapharma AG Key Developments
The Octapharma Group Announces Earnings Results for the Year 2016
Mar 1 17
The Octapharma Group announced earnings results for the year 2016. For the year, the company reported sales of €1.6 billion, which represents an increase of €87 million or 5.8% compared with 2015. Octapharma achieved an unprecedented operating income of €383 million.
Octapharma AG Announces Interim Data from Phase III Hemophilia A Study
Dec 21 16
Octapharma AG has announced interim data from the ongoing Phase III study, NuProtect, in patients with hemophilia A, at the 58th ASH Annual Meeting & Exposition in San Diego, California. The presentation was nominated for inclusion in the 2017 North American Highlights of ASH Roadshow meeting with an abstract published in Blood. The NuProtect Study examines the immunogenicity, efficacy and safety of treatment with human cell-line derived recombinant FVIII (Nuwiq) in previously untreated patients (PUPs) with severe haemophilia A. The presentation focused on immunogenicity of Nuwiq in 66 haemophilia A patients who have received at least 20 days of treatment in the ongoing NuProtect study, with no previous exposure to FVIII concentrates or other blood products. The cumulative incidence (95% confidence interval) of all inhibitors was 20.8% (10.7-31.0); 12.8% (4.5-21.2) for high-titre inhibitors and 8.4% (1.3-15.6) for low-tire inhibitors. These data were reported as part of a pre-planned interim analysis for the NuProtect study, which plans to ultimately evaluate at least 100 PUPs.
Octapharma Group Reports Earnings Results for the Year 2015
Mar 8 16
Octapharma Group reported earnings results for the year 2015. For the year, the company reported revenue of EUR 1.513 billion, representing an increase of EUR 233 million or 18.2% compared with the 2014. Operating income is reported at EUR 351 million. Net cash from operating activities is reported at EUR 382 million or 25% of revenue and provides the platform for future investments. Pre-tax profit was EUR 363 million. The investment in fixed assets was EUR 115 million in 2015. Adding the investments into research and development, in 2015 the Octapharma Group invested more than EUR 240 million into the future of the company.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries